Overall verdict
Sell
3.0/10
1-year performance
-3.34%
Score breakdown
Down 3.3% over 1 year, 13% of the 52-week range.
Strongest: Financial strength 10.0/10. Weakest: Shareholder return 0.0/10.
7 analysts, target +1.7% vs the price.
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension.
It also developing Almee, an investigational medical device in clinical development that has completed Phase III clinical stage to address the psychological impact of living with pulmonary fibrosis. It has a cooperation and development agreement with Emeriti Bio AB and HaLaCore Pharma AB to develop new follow-on molecules based on C21 and other drug substances targeting the AT2 receptor, as well as a collaboration and development agreement with Alex Therapeutics AB to develop a digital app in interstitial lung diseases, such as IPF. The company was formerly known as Mintage Scientific AB. Vicore Pharma Holding AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Sector
Health Care
Industry
Biotechnology
Primary listing
Omxsto
Sweden
CEO
Mr. Ahmed S. Mousa J.D.
Founded
2000
Employees
37
Revenue / employee
103 162 SEK
Next earnings
February 25, 2027
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
18.24 SEK
52-week low
8.56 SEK
1-year performance
-3.34%
Declining
Year-to-date performance
-12.92%
Declining
Drawdown
-46.05%
Major drawdown
Position in the 52-week range
13% of range
Gross margin 100.0%, the company loses 13397.1% of its revenue, ROIC -67.3%, ROE -67.3%.
Net margin
-13397.10%
Negative
Sector -212.24%|S&P 13.35%
Gross margin
100.00%
Exceptional
Return on equity (ROE)
-67.30%
Negative
Sector -55.30%|S&P 16.98%
Return on invested capital (ROIC)
-67.30%
Negative
Free cash flow margin (FCF)
-7936.60%
Negative
Margin stability
4279.6 pts
Very uneven
Revenue to net income
Growth
0.0/10Revenue down 21.8% over 1 year.
Revenue (trailing 12 months)
3.5M SEK
Revenue growth (1y)
-21.84%
Declining
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.87|S&P 0.84
Market cap
2.8Md SEK
Financial strength
10.0/10no net debt (net cash).
Net debt / EBITDA
—
Gearing (net debt / equity)
-106.42%
Net cash
Cash
710M SEK
Cash / market cap
25.61%
Very solid
Net debt
-710M SEK
Equity
667M SEK
Closed daily candles, 2 years
Last close on November 20, 2026: 9.84 SEK
- MM2010.11
- MM509.69
- MM20010.60
- RSI 1446.7
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-1.49%
200-day average slope, 3 months
-2.48%
50-day average slope, 1 month
-3.48%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
3.22 % per day
Volatility change
+2.08%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.70 (7) | -1.67 (6) | 5 (9) | -452 (3) | -452 (7) |
| 2027 | -1.64 (8) | -1.54 (7) | 42 (9) | -323 (4) | -453 (7) |
Amounts in millions of SEK, EPS in SEK per share. In brackets, the number of analysts. Consensus as of November 13, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | VICO | 3.0 | 1.5 | 271M USD | Not meaningful (loss) | -13397.1 % | -21.8 % | -67.3 % | — | -10.1 % | -3.3 % | ||
| 4 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 5 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 6 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 7 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 8 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
